- Home
- VTVT vs IAF Comparison
VTVT vs IAF Comparison
Compare VTVT & IAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VTVT | IAF |
|---|---|---|
| Founded | 2015 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.0M | 123.6M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | VTVT | IAF |
|---|---|---|
| Price | $34.63 | $12.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $37.00 | N/A |
| AVG Volume (30 Days) | 12.6K | ★ 90.4K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.44% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.15 | $3.60 |
| 52 Week High | $35.95 | $4.59 |
Technical Indicators
Market Signals| Indicator | VTVT | IAF |
|---|---|---|
| Relative Strength Index (RSI) | 70.06 | 66.43 |
| Support Level | $22.92 | $12.61 |
| Resistance Level | $35.95 | $12.83 |
| Average True Range (ATR) | 2.23 | 0.13 |
| MACD | 0.59 | -0.16 |
| Stochastic Oscillator | 89.87 | 79.03 |
Price Performance
Historical ComparisonAbout VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
About IAF abrdn Australia Equity Fund Inc.
Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.